A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)
| Sponsor: |
Nefro Avillion Clinical Development, LLC |
| Enrolling: |
Male and Female Patients |
| Study Length: |
1 Years |
| IRB Number: |
ACYY1906 |
| U.S. Govt. ID: |
NCT07508787 |
| Contact: |
Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu |
The goal of this clinical trial is to learn if an investigational medication called siplizumab can prevent rejection of a kidney transplant patients with end stage kidney disease. The study will compare two different doses of siplizumab to a medication that is standardly used post kidney transplant to prevent rejection, rabbit anti-thymocyte globulin (rATG). Participants will be followed for 1 year post transplant. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Investigator
Joshua Weiner, MD
| Are you between 18 and 70 years old? |
Yes |
No |
| Are you on the kidney transplant waiting list? |
Yes |
No |